This study is currently identifying potential collaborators for recruitment efforts.

If you want to receive updates about grants or potential research opportunities subscribe to our Clinical Research Network

COVID-19 drugs
  • Title: ACTIV-6: COVID-19 Study of Repurposed Medications

    ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States through its website,, and call center, 1-833-385-1880.

    The study is now testing these repurposed medications: Ivermectin, used to treat parasitic infections; Fluticasone, an inhaled steroid commonly prescribed for asthma and chronic obstructive pulmonary disease; and Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), often prescribed for depression.

    • Principal Investigator: Adrian Hernandez, MD, MHS Duke Clinical Research Institute Email:
    • Co-Principal Investigator/IND Sponsor: Susanna Naggie, MD, MHS Duke Clinical Research Institute  Email:
    • Data Coordinating Center Investigator Chris Lindsell, PhD Vanderbilt University School of Medicine Email:

    Funding Agency: National Center for Advancing Translational Sciences

    For more information, please access the website or contact: